期刊文献+

恩度不同给药时相联合放疗对胃癌裸鼠移植瘤抑制及其机制研究

Endostar Given at Different Times Combined with Radiotherapy to the Effect of Gastric Cancer Transplanted in Mice and Its Possible Mechanism
下载PDF
导出
摘要 目的:观察恩度不同给药时相联合放疗对胃癌裸鼠移植瘤的抑制作用,并对其可能机制进行探讨。方法:建立MFC小鼠胃癌移植瘤模型,随机分成5组:对照组、RT1 + NS组、RT1 + ES组、RT7 + ES组、RT14 + ES组,分别于放疗期间采用生理盐水及恩度干预。于治疗的第8、15天各处死5只小鼠,取出肿瘤,观察并测量各组肿瘤体积变化,绘制肿瘤生长曲线,计算抑瘤率,采用免疫组化方法检测各组肿瘤组织中VEGF、HIF-1α及PCNA的表达情况。结果:RT1 + ES组及RT7 + ES组较其他组肿瘤生长慢、抑瘤率高,差异有统计学意义(P 【0.05);实验第8天和第15天,VEGF与PCNA蛋白的表达在恩度联合放疗组均有不同程度下降,尤以RT1 + ES组及RT7 + ES组PCNA表达下降最明显,差异有统计学意义(P 【0.05)。结论:恩度联合放疗可能通过调节VEGF、HIF-1α及PCNA的表达等机制,对胃癌裸小鼠发挥肿瘤抑制作用。在恩度第7天行放疗或第1天同步放疗,对胃癌裸鼠移植瘤抑制作用最强。 Objective: The aim of this study was to observe the inhibitory effect of endostar given at different times combined with radiotherapy on gastric cancer xenografts in nude mice, and to explore its possible mechanism. Methods: MFC mouse gastric cancer xenograft models were established and randomly divided into 5 groups: control group, RT1 + NS group, RT1 + ES group, RT7 + ES group, RT14 + ES group. Physiological saline and Endo intervention during radiotherapy, on the 8th and 15th day of treatment, 5 mice were sacrificed, tumors were taken out, tumor volume changes were observed and measured, tumor growth curves were drawn, tumor inhibition rate was calculated. VEGF, HIF-1α and PCNA were observed by Immunohistochemistry. Results: The tumor growth of RT1 + ES group and RT7 + ES group was slower and the tumor inhibition rate was higher (P
出处 《临床医学进展》 2020年第3期399-405,共7页 Advances in Clinical Medicine
  • 相关文献

参考文献1

二级参考文献13

  • 1Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J]. Exp Cell Res, 2006, 312(5): 594-607.
  • 2Zhuang HO~ Yuan ZY. Process in the mechanisms of endostatin combined with radiotherapy[J].Cancer Lett, 2009, 282(1): 9-13.
  • 3Itasaka S, Komaki R, Herbst RS, et al. Endostatin improves radiore- sponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice[J] . Int J Radiat Oncol Biol Phys, 2007, 67(3): 870-878.
  • 4Sweet IR, Yanay O, Waldron L, et al. Treatment of diabetic rats with encapsulated islets[J].J Cell Mol Med. 2008, 12(6B): 2644-2650.
  • 5LouJ, HeJ, Jin L, et al. Measuring the genetic damage in cancer pa- tients during radiotherapy with three genetic end-points[J].Muta- genesis, 2004, 19(6): 457-464.
  • 6Nieder C, Wiedenmann N, Andratschke N, et al. Current status of angiogenesis inhibitors combined with radiation therapy[J].Cancer Treat Rev, 2006, 32(5): 348-364.
  • 7Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombi- nant human endostatin in patients with advanced solid tumors[J]. J Clin Oncol, 2002, 20(18): 3792-3803.
  • 8Citrin D, M6nard C, Camphausen K. Combining radiotherapy and angiogenesis inhibitors: clinical trial design[J].IntJ Radiat Oncol Bi- ol Phys, 2006, 64(1): 15-25.
  • 9Tolstanova G, Deng X, Khomenko T, et al. Role of anti-angiogen- ic factor endostatin in the pathogenesis of experimental ulcerative colitis[J]. Life Sci, 2011, 88(1-2): 74-81.
  • 10FolkmanJ. Angiogenesis: an organizing principle for drug discovery[J]? Nat Rev Drug Discov, 2007, 6(4): 273-286.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部